Effect of Semaglutide 2.4 mg once-weekly on function and symptoms in subjects with obesity-related heart failure with preserved ejection fraction, and type 2 diabetes
Latest Information Update: 08 Jul 2024
At a glance
- Drugs Semaglutide (Primary)
- Indications Heart failure; Obesity; Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms STEP HFpEF DM
- Sponsors Novo Nordisk
- 18 Jun 2024 According to Novo Nordisk media release, the company announced that the data of this trial will be discussed at the upcoming 84th Scientific Sessions of the American Diabetes Association (ADA). The conference will be held in-person and virtually from 21 to 24 June 2024 in Orlando, US.
- 07 Apr 2024 Results of prespecified pooled analysis of the STEP-HFpEF (n=529; Between March 19, 2021 and March 9, 2022) and STEP-HFpEF DM (n=616; between June 27, 2021 and Sept 2, 2022) trials, assessing the effects of semaglutide across a broad range of outcomes in people with obesity-related heart failure with preserved ejection fraction with and without diabetes, and to assess whether these effects are consistent across key patient subgroups published in the Lancet
- 30 Oct 2023 Status changed from recruiting to completed.